Drug Research

The benefits of earlier detection and quicker access to treatments will be felt by cancer patients as well as newborns with curable but uncommon genetic illnesses. It comes after the UK health and social care secretary pledged a £175...

The first gene therapy for non-muscle invasive bladder cancer (NMIBC) in individuals with high-risk carcinoma in situ (CIS) with or without papillary tumours has been licenced by the US Food and Drug Administration (FDA) as Adstiladrin (nadofaragene firadenovec-vncg). Adstiladrin,...

The agency that suggests which medications should be allowed in Europe has backed five new ones, including a gene therapy for haemophilia, a combo treatment for liver cancer, and a drug for the uncommon condition known as Pompe disease. The...

The World Health Organization (WHO) has released its revised consolidated recommendations for treating drug-resistant tuberculosis (DR-TB), which include significant advancements in the treatment options available to individuals with MDR or RR-TB: multidrug-resistant or rifampicin-resistant tuberculosis) and a regimen that...

The global Alzheimer's therapeutics market is anticipated to develop at a compound annual growth rate (CAGR) of 9.3% and reach $6.8 billion by 2032, according to a report by Future Market Insights (FMI). According to the estimate, the global market for...

Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions of this product to enter the market. Often presenting a more cost-effective alternative, biosimilars can provide greater access to...

Syneos Health, the only fully integrated biopharmaceutical solutions organization, announced it has extended its strategic partnership with Medable, the industry-leading technology platform for patient-centered clinical trials, as part of the Company’s commitment to bring clinical trials closer to the...